Nausea on Wegovy (semaglutide 2.4 mg): Incidence, Severity, and Realistic Expectations

How common is nausea on Wegovy?

The Wegovy label pools three placebo-controlled trials in adults with obesity or overweight: 2,116 people took semaglutide 2.4 mg once weekly and 1,261 took placebo, for up to 68 weeks [1]. Nausea was reported by 44% of adults on Wegovy 2.4 mg versus 16% on placebo [1]. Diarrhea was 30% versus 16%, vomiting 24% versus 6%, constipation 24% versus 11% and abdominal pain 20% versus 10% [1]. Overall, 73% on Wegovy 2.4 mg and 47% on placebo reported at least one gastrointestinal reaction [1].

How severe does the nausea get?

The label reports severe gastrointestinal reactions as one grouped figure: 4.1% of adults on the 2.4 mg injection versus 0.9% on placebo [1]. It does not split nausea into mild, moderate and severe on its own. In the 104-week STEP 5 trial (152 adults per arm), gastrointestinal events were mostly mild to moderate, though more frequent on semaglutide than placebo (82.2% versus 53.9%) [3].

Nausea was also the adverse reaction that most often led to stopping among those the label lists. Permanent discontinuation for any adverse reaction was 6.8% versus 3.2%; nausea accounted for 1.8% versus 0.2%, vomiting 1.2% versus 0%, and diarrhea 0.7% versus 0.1% [1]. That works out to about 18 people per 1,000 on Wegovy stopping for nausea, against about 2 per 1,000 on placebo. In STEP 1 (1,961 adults without diabetes, 68 weeks), 4.5% on semaglutide 2.4 mg stopped because of gastrointestinal events versus 0.8% on placebo [2].

Does nausea get worse at higher doses?

Modestly. The label also describes two 72-week trials of a 7.2 mg weekly dose, 2.4 mg and placebo in 1,311, 304 and 303 adults with obesity respectively [1]. Nausea was reported by 39% on 7.2 mg, 35% on 2.4 mg and 13% on placebo; vomiting by 22%, 16% and 6% [1]. Discontinuation for any adverse reaction was 5%, 5% and 2%, and for gastrointestinal reasons 3%, 3% and 0.3% [1]. The 35% on 2.4 mg here is lower than the 44% in the pooled trials; the label cautions that adverse reaction rates from different trials cannot be compared directly [1].

When does nausea start, and how long does it last?

The label does not report a time to first nausea or a typical duration [1]. What it does give is the titration schedule: 0.25 mg weekly for weeks 1 to 4, 0.5 mg for weeks 5 to 8, 1 mg for weeks 9 to 12, 1.7 mg for weeks 13 to 16, then a maintenance dose from week 17, with the stated aim of reducing the risk of gastrointestinal adverse reactions [1].

Which serious problems can come with stomach symptoms?

The Wegovy label's warnings include several conditions linked to gastrointestinal symptoms:

• Acute pancreatitis. The label says to watch for persistent severe abdominal pain, sometimes radiating to the back, which may or may not be accompanied by nausea or vomiting, and to discontinue Wegovy and start appropriate management if pancreatitis is suspected [1]. Confirmed acute pancreatitis occurred in 4 Wegovy-treated adults (0.2 per 100 patient-years) versus 1 on placebo [1].
• Acute kidney injury from volume depletion. The label says to monitor renal function in patients reporting adverse reactions that could lead to volume depletion [1]. Acute kidney injury occurred in 0.4 versus 0.2 cases per 100 patient-years, more often in people with existing kidney impairment and during dose titration, often after gastrointestinal fluid loss [1].
• Severe constipation and bowel obstruction. Postmarketing reports for the semaglutide labels include ileus, intestinal obstruction and severe constipation with fecal impaction, and the label says Wegovy is not recommended in people with severe gastroparesis [1].
• Gallbladder disease. Cholelithiasis was reported by 1.6% on Wegovy injection versus 0.7% on placebo, and cholecystitis by 0.6% versus 0.2% [1].

Can you stay on a lower dose?

The label lists two maintenance doses for weight reduction in adults: 2.4 mg once weekly, which is the recommended dose, or 1.7 mg [1]. For the MASH indication it specifies 2.4 mg, with the option of reducing to 1.7 mg [1]. During escalation, the label says that if a dose is not tolerated, consider delaying escalation for 4 weeks [1]. Adults who tolerate 2.4 mg for at least four weeks and need more weight loss may go up to a maximum of 7.2 mg weekly [1].

Does the Wegovy tablet cause nausea too?

Yes. In a 64-week trial, 204 adults with obesity or overweight and no diabetes received Wegovy 25 mg tablets. The label states that the types and frequencies of adverse reactions were similar to the injection table, with severe gastrointestinal reactions in 2% versus 0% on placebo [1].